Published in PLoS One on October 10, 2012
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics. Neoplasia (2013) 1.17
Pancreatic cancer-associated retinoblastoma 1 dysfunction enables TGF-β to promote proliferation. J Clin Invest (2013) 1.10
Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget (2015) 1.01
A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges. PLoS One (2013) 0.98
Therapeutic options for the management of pancreatic cancer. World J Gastroenterol (2014) 0.96
Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers. Oncotarget (2015) 0.96
Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts. World J Gastroenterol (2014) 0.87
The role of quantitative mass spectrometry in the discovery of pancreatic cancer biomarkers for translational science. J Transl Med (2014) 0.84
Tunneling nanotubes: an alternate route for propagation of the bystander effect following oncolytic viral infection. Mol Ther Oncolytics (2016) 0.84
Evidence for the importance of personalized molecular profiling in pancreatic cancer. Pancreas (2014) 0.83
Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines. Cancer Med (2015) 0.80
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. BMC Cancer (2014) 0.79
Integrated Genomic Analysis of Pancreatic Ductal Adenocarcinomas Reveals Genomic Rearrangement Events as Significant Drivers of Disease. Cancer Res (2015) 0.79
Identification and characterization of the gene expression profiles for protein coding and non-coding RNAs of pancreatic ductal adenocarcinomas. Oncotarget (2015) 0.78
Capture-based next-generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing. Mol Genet Genomic Med (2016) 0.77
Characterization of X chromosome inactivation using integrated analysis of whole-exome and mRNA sequencing. PLoS One (2014) 0.77
Globally increased ultraconserved noncoding RNA expression in pancreatic adenocarcinoma. Oncotarget (2016) 0.76
Advances in systemic therapy for advanced pancreatobiliary malignancies. F1000Res (2013) 0.75
From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. Int J Mol Sci (2017) 0.75
Diagnosis of pancreatic lesions collected by endoscopic ultrasound-guided fine-needle aspiration using next-generation sequencing. Oncol Lett (2016) 0.75
Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer. BMC Med Genomics (2014) 0.75
A data mining approach for identifying pathway-gene biomarkers for predicting clinical outcome: A case study of erlotinib and sorafenib. PLoS One (2017) 0.75
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Database resources of the National Center for Biotechnology Information. Nucleic Acids Res (2000) 34.79
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (1996) 11.13
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell (1988) 10.29
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med (2004) 6.91
Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet (2006) 6.71
CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods (2011) 5.34
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A (1996) 4.39
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res (2009) 3.57
Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res (1997) 3.55
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell (2007) 3.37
BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst (2003) 3.37
Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res (1998) 2.89
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood (2012) 2.88
ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics (2011) 2.74
Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med (2011) 2.59
CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood (2011) 2.52
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer (1991) 2.52
Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci U S A (1997) 2.36
Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia (2005) 2.35
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet (2011) 2.32
Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol (2001) 2.21
Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep (2011) 2.09
The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res (2003) 2.01
Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res (2007) 1.98
Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol (2002) 1.96
Integrative genomics reveals mechanisms of copy number alterations responsible for transcriptional deregulation in colorectal cancer. Genes Chromosomes Cancer (2009) 1.91
Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A (2010) 1.84
Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood (2007) 1.83
Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut (2008) 1.82
Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A (2012) 1.82
Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. Genes Chromosomes Cancer (2002) 1.81
Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol (1993) 1.80
Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res (2000) 1.80
High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer (1989) 1.79
Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res (1998) 1.78
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci U S A (2009) 1.71
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res (2009) 1.57
Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Res (1992) 1.55
Genome profiling of pancreatic adenocarcinoma. Genes Chromosomes Cancer (2011) 1.54
Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res (2004) 1.44
An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist (2011) 1.44
Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer (2007) 1.42
p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene (1998) 1.41
Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors. Cancer Res (1998) 1.40
Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol (2001) 1.39
The c-erb B-2 proto-oncogene in human pancreatic cancer. J Pathol (1990) 1.39
Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer (2001) 1.36
In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res (2007) 1.35
Nuclear protein 1 promotes pancreatic cancer development and protects cells from stress by inhibiting apoptosis. J Clin Invest (2012) 1.33
S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res (2007) 1.33
Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Ther (2011) 1.31
Overexpression of FMNL2 is closely related to metastasis of colorectal cancer. Int J Colorectal Dis (2008) 1.28
Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer. Int J Cancer (2007) 1.26
Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. Oncol Rep (2009) 1.24
Spliceosome mutations in hematopoietic malignancies. Nat Genet (2011) 1.23
Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res (2010) 1.23
Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res (2008) 1.22
Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol (2001) 1.22
The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. Gastroenterology (2011) 1.19
Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prev (2011) 1.19
Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer (2002) 1.19
Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. Am J Hum Genet (2002) 1.17
High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol (2007) 1.17
The RNA binding protein Larp1 regulates cell division, apoptosis and cell migration. Nucleic Acids Res (2010) 1.17
Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. Oncogene (2006) 1.15
A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther (2010) 1.13
Mutations of the adenomatous polyposis coli gene in the mutation cluster region: comparison of human pancreatic and colorectal cancers. Int J Cancer (1994) 1.11
DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma. Cancer Genet Cytogenet (2000) 1.09
Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers. FASEB J (2005) 1.09
Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur J Cancer (2001) 1.07
Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology (1996) 1.05
Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol (2007) 1.03
The significance of LMO2 expression in the progression of prostate cancer. J Pathol (2007) 1.02
Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma. Oncogene (2011) 1.01
Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer. Hum Pathol (2012) 1.01
Sonic hedgehog derived from human pancreatic cancer cells augments angiogenic function of endothelial progenitor cells. Cancer Sci (2008) 1.01
FMNL2 is a positive regulator of cell motility and metastasis in colorectal carcinoma. J Pathol (2011) 1.00
HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol (2006) 1.00
FMNL2 enhances invasion of colorectal carcinoma by inducing epithelial-mesenchymal transition. Mol Cancer Res (2010) 1.00
Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Ann Oncol (2009) 0.99
Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries. Ann Oncol (2011) 0.99
Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: Involvement of regulation of LIF and its receptor expression. Int J Oncol (2007) 0.98
Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth. Oncogene (2011) 0.98
BRCA2 and pancreatic cancer. Int J Gastrointest Cancer (2002) 0.98
Association of matrilysin mRNA expression with K-ras mutations and progression in pancreatic ductal adenocarcinomas. Carcinogenesis (2001) 0.97
LMO2 is a novel predictive marker for a better prognosis in pancreatic cancer. Neoplasia (2009) 0.96
Zinc-finger protein 331, a novel putative tumor suppressor, suppresses growth and invasiveness of gastric cancer. Oncogene (2012) 0.95
Loss of CDKN2A and p14ARF expression occurs frequently in human nonmelanoma skin cancers. Br J Dermatol (2007) 0.93
Involvement of RQCD1 overexpression, a novel cancer-testis antigen, in the Akt pathway in breast cancer cells. Int J Oncol (2009) 0.93
Leukemia inhibitory factor receptor (LIFR) is detected as a novel suppressor gene of hepatocellular carcinoma using double-combination array. Cancer Lett (2009) 0.93
Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. Cancer Gene Ther (2008) 0.93
Resolving individuals contributing trace amounts of DNA to highly complex mixtures using high-density SNP genotyping microarrays. PLoS Genet (2008) 20.38
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med (2013) 16.24
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2003) 12.24
A survey of genetic human cortical gene expression. Nat Genet (2007) 12.04
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol (2007) 7.73
Mapping of sudden infant death with dysgenesis of the testes syndrome (SIDDT) by a SNP genome scan and identification of TSPYL loss of function. Proc Natl Acad Sci U S A (2004) 7.70
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry (2007) 7.23
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol (2005) 6.98
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol (2010) 6.34
Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 6.31
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med (2012) 5.92
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol (2009) 5.73
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol (2011) 5.43
Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med (2014) 5.33
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet (2012) 4.85
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 4.75
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
POEMS syndrome: definitions and long-term outcome. Blood (2002) 4.35
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol (2003) 4.34
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res (2011) 4.05
Genetic control of individual differences in gene-specific methylation in human brain. Am J Hum Genet (2010) 3.91
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol (2003) 3.88
New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation (2003) 3.79
Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet (2008) 3.79
Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies. Am J Hum Genet (2006) 3.67
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol (2008) 3.66
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood (2011) 3.58
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol (2004) 3.43
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol (2005) 3.41
AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med (2013) 3.41
Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet (2009) 3.35
Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med (2007) 3.33
Common Kibra alleles are associated with human memory performance. Science (2006) 3.30
Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage (2010) 3.27
Association of Clinical Researchers and Educators a statement on relationships between physicians and industry. Endocr Pract (2012) 3.27
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol (2006) 3.00
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood (2012) 2.98
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood (2004) 2.97
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov (2013) 2.88
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood (2007) 2.87
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell (2008) 2.84
Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement (2010) 2.79
Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat Genet (2009) 2.73
Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet (2011) 2.70
Voxelwise genome-wide association study (vGWAS). Neuroimage (2010) 2.69
Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med (2005) 2.67
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol (2002) 2.63
Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J Am Soc Nephrol (2011) 2.63
Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc (2004) 2.62
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol (2008) 2.58
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc (2007) 2.55